Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

about

MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1 Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

P2860

Q58732696-0DA56D83-FC15-4C44-9781-D073DFCAA84A Q58795231-B2E11F20-9B8E-4D3C-8D10-06F170C97F47

P2860

Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q55503616

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

@en

Immunotherapy combination strategies

@nl

type

Item

label

Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

@en

Immunotherapy combination strategies

@nl

prefLabel

Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

@en

Immunotherapy combination strategies

@nl

P1476

Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

@en

P2093

Andreas Saltos

http://www.w3.org/2001/XMLSchema#string

Jhanelle E Gray

http://www.w3.org/2001/XMLSchema#string

Sandrine Niyongere

http://www.w3.org/2001/XMLSchema#string

P2860

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Hallmarks of Cancer: The Next Generation

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

Nivolumab plus ipilimumab in advanced melanoma.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

P304

S433-S450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2017.12.120

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29593889

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5861267

http://www.w3.org/2001/XMLSchema#string

Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

about

P2860

P2860

Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932